Delivery of polynucleotide agents to the central nervous system
AssigneeChiron Corporation
InventorsChristoph Reinhard, William H. Frey II
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for delivering polynucleotide agents, particularly oligonucleotides, to the CNS of a mammal by way of a neural pathway originating in the nasal cavity or through a neural pathway originating in an extranasal tissue that is innervated by the trigeminal nerve.
Claims23
A method for delivering a polynucleotide agent to the central nervous system of a mammal, comprising:
- contacting an olfactory region of a nasal cavity or a tissue innervated by a trigeminal nerve with a composition comprising the agent whereby the agent is delivered to the tissues and cells of the central nervous system.
A method for administering a polynucleotide agent to the central nervous system of a mammal, comprising:
- administering a composition comprising an effective amount of the agent to an olfactory region of a nasal cavity or to a tissue that is innervated by the trigeminal nerve, whereby the agent is transported into the central nervous system of the mammal in an amount effective to provide a diagnostic, protective, or therapeutic effect on a cell of the central nervous system.
A method of inhibiting translation of a mRNA that encodes a target protein that contributes to the pathology of a central nervous system disorder of a mammal, comprising:
- providing a composition comprising at least one antisense agent that is complementary to a region of the mRNA;
- and contacting the composition with an olfactory region of the mammal's nasal cavity or with a tissue that is innervated by the trigeminal nerve, whereby the antisense agent is delivered to a cell of the central nervous system that comprises the mRNA, wherein the antisense agent hybridizes to the target mRNA and inhibits translation.
Dependencies are inferred from the claim text.